Heart Test Laboratories, Inc. (HSCS)
Market Cap | 7.68M |
Revenue (ttm) | 18,600 |
Net Income (ttm) | -6.39M |
Shares Out | 65.56M |
EPS (ttm) | -0.48 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,361,974 |
Open | 0.120 |
Previous Close | 0.117 |
Day's Range | 0.115 - 0.121 |
52-Week Range | 0.111 - 1.490 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Mar 14, 2024 |
About HSCS
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas. [Read more]
Financial Performance
In 2023, HSCS's revenue was $5,150, a decrease of -64.17% compared to the previous year's $14,373. Losses were -$6.35 million, 31.6% more than in 2022.
Financial StatementsNews
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LV...
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered me...
HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screening Data Demonstrated MyoVista AI-ECG...
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered me...
HeartSciences Adds Key Advisor to its Scientific Advisory Board
Southlake, TX, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered med...
HeartSciences Expands its Scientific Advisory Board
Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered med...
HeartSciences Appoints New Scientific Advisory Board Member
Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered med...
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered med...
HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
Southlake, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), would like to remind its shareholders to v...
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered med...
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
Southlake, TX, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered med...
HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology compan...
Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
Southlake, TX, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medi...
HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase
Southlake, TX, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medi...
HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards
Southlake, TX, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medi...
HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India
Southlake, TX, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based med...
HeartSciences Signs Distribution Agreement with FJ Medical, Denmark
Southlake, TX, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medi...
HeartSciences' MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation
Southlake, TX, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medi...
HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio
European Patent Allowed for Quantification by an ECG of Key Heart Measures using AI European Patent Allowed for Quantification by an ECG of Key Heart Measures using AI
MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark
Southlake, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based m...
HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results
Southlake, Texas, July 19, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based m...
HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine
Southlake, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based med...
HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG
Southlake, Texas, May 09, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based med...
HeartSciences to Participate at the Inaugural EF Hutton Global Conference
Southlake, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based me...